Ignite Creation Date:
2025-12-25 @ 3:39 AM
Ignite Modification Date:
2025-12-26 @ 2:23 AM
Study NCT ID:
NCT07279402
Status:
RECRUITING
Last Update Posted:
2025-12-12
First Post:
2025-12-01
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
Sponsor:
Antalya Training and Research Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-09-15
Start Date Type:
ACTUAL
Primary Completion Date:
2027-05-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-10-01
Completion Date Type:
ESTIMATED
First Submit Date:
2025-12-01
First Submit QC Date:
None
Study First Post Date:
2025-12-12
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-01
Last Update Post Date:
2025-12-12
Last Update Post Date Type:
ESTIMATED